The reimbursement decision speed for oncology new drugs in China and its determinant factors
IntroductionChina has initiated national price negotiations to improve access to innovative drugs. Learning the factors that contributed to the time gap from marketing authorization to reimbursement leads to more clarity to decision-making, which remains under-researched in China.MethodsWe collected...
Saved in:
Main Authors: | Xingyue Zhu (Author), Yang Chen (Author) |
---|---|
Format: | Book |
Published: |
Frontiers Media S.A.,
2023-10-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Review time of oncology drugs and its underlying factors: an exploration in China
by: Xingyue Zhu, et al.
Published: (2023) -
Bridging the new drug access gap between China and the United States and its related policies
by: Xingyue Zhu, et al.
Published: (2024) -
Were economic evaluations well reported for the newly listed oncology drugs in China's national reimbursement drug list
by: Liu Liu, et al.
Published: (2022) -
Correlation between clinical trial endpoints of marketed cancer drugs and reimbursement decisions in China
by: Kexin Ling, et al.
Published: (2022) -
Drug pricing and reimbursement decision making systems in Mongolia
by: Gereltuya Dorj, et al.
Published: (2017)